This article was originally published in The Rose Sheet
Executive SummaryMedical and therapeutic skincare company Langer will expand into additional personal care categories with its acquisition of private label manufacturer Twincraft early next year, firm states in Nov. 14 release. Valued at $26.7 mil., the transaction is expected to close in the first quarter of 2007, Langer says. The acquisition of Twincraft, producer of specialty bar soap, will bring Langer into the health and beauty, amenities, mass and direct marketing channels, firm notes. The soap manufacturer grossed revenues of approximately $27.1 mil. for fiscal year 2005. For the nine months ended Sept. 30, the firm reported revenues of $20.7 mil. Twincraft President and CEO Peter Asch is expected to join Langer's board of directors. The firm employs approximately 200 people in its Winooski and Essex Junction, Vt., locations. The business is expected to remain in Vermont...
You may also be interested in...
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.